WASHINGTON The Food and Drug Administration today approved Cimzia, a new drug by UCB to treat Crohn’s disease. Crohn’s disease is a chronic, inflammatory bowel disease. It has no cure and its cause is ...

May 27, 2009 — The US Food and Drug Administration (FDA) has approved risperidone long-acting injection for use alone or with lithium or valproate in the treatment of bipolar I disorder; and ...

ATLANTA, Oct. 18, 2013 -- regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adults with active ...

UCB (UCB.BR) The European marketing authorisation application for Cimzia® has been filed. Subject to approval, Cimzia® will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor ...

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...

WASHINGTON, April 22 (UPI) -- The U.S. Food and Drug Administration announced approval Tuesday of a new drug, Cimzia, to help sufferers of Crohn's disease. The FDA approved Cimzia (certolizumab pegol) ...

* EMA has recommended the Cimzia dose dispenser cartridge for use with the re-usable ava electronic injection device in all approved indications Source text: bit.ly/2qcXlVg Further company coverage: ...

Cimzia (certolizumab pegol injection, from UCB) has been approved by the FDA for the treatment of moderate-to-severe Crohn’s disease (CD) when conventional therapies have failed. This approval is ...

The FDA has approved Cimzia (certolizumab pegol; UCB) injection for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the first ...